Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE: Aspirin Discontinuation in Elderly Patients With Stable Ischemic Heart Disease
2026-525442-30-00Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aspirin in coronary arteriosclerosis, Chronic Coronary Syndrome (CCS) and myocardial infarction (MI) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Hierarchical composite primary endpoint. Planned start Sep 2026; status: authorised.
02
Drugs
aspirin
03
Conditions
coronary arteriosclerosisChronic Coronary Syndrome (CCS)myocardial infarction (MI)
Beyond the preview
Go deeper on 2026-525442-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525442-30-00.